FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129485026> ?p ?o ?g. }

• W2129485026 endingPage "4142" @default.
• W2129485026 startingPage "4137" @default.
• W2129485026 abstract "Background: The aim of this study was to evaluate the activity and toxicity of epirubicin and cyclophosphamide (EC) followed by docetaxel as primary systemic chemotherapy (PST) in locally advanced breast cancer. Patients and Methods: In this phase II trial, 46 patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (90 mg/m 2 ) and cyclophosphamide (600 mg/m 2 ) every 3 weeks for four cycles, followed by docetaxel (70 mg/m 2 ) every 3 weeks for four cycles. Primary endpoints were pathologic al and objective response in the breast and axilla, and toxicities. Results: The clinical response rate was 80.4% (95% confidence interval, 68.9- 91.9% ). Pathological response evaluation revealed 6 complete responses (CR: 13.0%). Patients with ER-negative tumors had a significantly higher rate of pathological CR than the others (33.3% vs. 3.2% ; p=0.0105). Febrile neutropenia occurred in 4 patients (8.7%). Conclusion: EC followed by docetaxel is an active and well-tolerated treatment as PST for locally advanced breast cancer. Primary systemic chemotherapy (PST) is now widely used as the treatment of patients with operable as well as inoperable breast cancer (1-5). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 trial clarified that preoperative chemotherapy never shortens survival time compared with postoperative chemotherapy (6). This trial also demonstrated that pathological tumor response was predictive of overall survival, suggesting that preoperative chemotherapy would take advantage of controlling micrometastasis and drug delivery to cancer cells. Thus, PST is now considered to be standard therapy for the treatment of high-risk breast cancer. It is clear that the anthracyclines are the most standard and active drugs for breast cancer. Anthracycline-based regimens include doxorubicin and cyclophosphamide (AC), epirubicin and cyclophosphamide (EC), and 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Although anthracycline-based preoperative chemotherapy showed a good response rate, a pathological complete response (pCR) rate was not achieved (6-9)." @default.
• W2129485026 created "2016-06-24" @default.
• W2129485026 creator A5004205569 @default.
• W2129485026 creator A5029758773 @default.
• W2129485026 creator A5043771878 @default.
• W2129485026 creator A5067226989 @default.
• W2129485026 creator A5074455781 @default.
• W2129485026 creator A5080578342 @default.
• W2129485026 creator A5080597947 @default.
• W2129485026 creator A5080612054 @default.
• W2129485026 creator A5081758735 @default.
• W2129485026 date "2008-11-01" @default.
• W2129485026 modified "2023-09-30" @default.
• W2129485026 title "Epirubicin and Cyclophosphamide Followed by Docetaxel as Primary Systemic Chemotherapy in Locally Advanced Breast Cancer" @default.
• W2129485026 cites W141170814 @default.
• W2129485026 cites W1841504999 @default.
• W2129485026 cites W1986292173 @default.
• W2129485026 cites W1986888455 @default.
• W2129485026 cites W1994513862 @default.
• W2129485026 cites W2015654855 @default.
• W2129485026 cites W2022915103 @default.
• W2129485026 cites W2040830201 @default.
• W2129485026 cites W2068724174 @default.
• W2129485026 cites W2069878819 @default.
• W2129485026 cites W2104337757 @default.
• W2129485026 cites W2114886993 @default.
• W2129485026 cites W2131686669 @default.
• W2129485026 cites W2131915049 @default.
• W2129485026 cites W2133764807 @default.
• W2129485026 cites W2139248078 @default.
• W2129485026 cites W2139510434 @default.
• W2129485026 cites W2140654333 @default.
• W2129485026 cites W2153158488 @default.
• W2129485026 cites W2162760540 @default.
• W2129485026 cites W2163590844 @default.
• W2129485026 cites W2183598873 @default.
• W2129485026 cites W2398202108 @default.
• W2129485026 cites W3146687936 @default.
• W2129485026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19192673" @default.
• W2129485026 hasPublicationYear "2008" @default.
• W2129485026 type Work @default.
• W2129485026 sameAs 2129485026 @default.
• W2129485026 citedByCount "8" @default.
• W2129485026 countsByYear W21294850262013 @default.
• W2129485026 countsByYear W21294850262014 @default.
• W2129485026 countsByYear W21294850262015 @default.
• W2129485026 countsByYear W21294850262018 @default.
• W2129485026 crossrefType "journal-article" @default.
• W2129485026 hasAuthorship W2129485026A5004205569 @default.
• W2129485026 hasAuthorship W2129485026A5029758773 @default.
• W2129485026 hasAuthorship W2129485026A5043771878 @default.
• W2129485026 hasAuthorship W2129485026A5067226989 @default.
• W2129485026 hasAuthorship W2129485026A5074455781 @default.
• W2129485026 hasAuthorship W2129485026A5080578342 @default.
• W2129485026 hasAuthorship W2129485026A5080597947 @default.
• W2129485026 hasAuthorship W2129485026A5080612054 @default.
• W2129485026 hasAuthorship W2129485026A5081758735 @default.
• W2129485026 hasConcept C121608353 @default.
• W2129485026 hasConcept C126322002 @default.
• W2129485026 hasConcept C141071460 @default.
• W2129485026 hasConcept C143998085 @default.
• W2129485026 hasConcept C203092338 @default.
• W2129485026 hasConcept C2775930923 @default.
• W2129485026 hasConcept C2776694085 @default.
• W2129485026 hasConcept C2776755627 @default.
• W2129485026 hasConcept C2777063308 @default.
• W2129485026 hasConcept C2778850193 @default.
• W2129485026 hasConcept C2780835546 @default.
• W2129485026 hasConcept C2781190966 @default.
• W2129485026 hasConcept C530470458 @default.
• W2129485026 hasConcept C535046627 @default.
• W2129485026 hasConcept C71924100 @default.
• W2129485026 hasConceptScore W2129485026C121608353 @default.
• W2129485026 hasConceptScore W2129485026C126322002 @default.
• W2129485026 hasConceptScore W2129485026C141071460 @default.
• W2129485026 hasConceptScore W2129485026C143998085 @default.
• W2129485026 hasConceptScore W2129485026C203092338 @default.
• W2129485026 hasConceptScore W2129485026C2775930923 @default.
• W2129485026 hasConceptScore W2129485026C2776694085 @default.
• W2129485026 hasConceptScore W2129485026C2776755627 @default.
• W2129485026 hasConceptScore W2129485026C2777063308 @default.
• W2129485026 hasConceptScore W2129485026C2778850193 @default.
• W2129485026 hasConceptScore W2129485026C2780835546 @default.
• W2129485026 hasConceptScore W2129485026C2781190966 @default.
• W2129485026 hasConceptScore W2129485026C530470458 @default.
• W2129485026 hasConceptScore W2129485026C535046627 @default.
• W2129485026 hasConceptScore W2129485026C71924100 @default.
• W2129485026 hasLocation W21294850261 @default.
• W2129485026 hasLocation W21294850262 @default.
• W2129485026 hasOpenAccess W2129485026 @default.
• W2129485026 hasPrimaryLocation W21294850261 @default.
• W2129485026 hasRelatedWork W1983310681 @default.
• W2129485026 hasRelatedWork W2062968551 @default.
• W2129485026 hasRelatedWork W2121706023 @default.
• W2129485026 hasRelatedWork W2158594487 @default.
• W2129485026 hasVolume "28" @default.
• W2129485026 isParatext "false" @default.
• W2129485026 isRetracted "false" @default.

• next